首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1535964

白介素抑制劑市場- 按類型（IL-1、IL-2、IL-5、IL-6、IL-17 和IL-23 抑制劑）、給藥途徑（皮下、靜脈注射）、應用（類風濕關節炎、牛皮癬、 IBD、氣喘），最終用戶 - 全球預測 2024 - 2032

Interleukin Inhibitors Market - By Type (IL-1, IL-2, IL-5, IL-6, IL-17, & IL-23 Inhibitors), Route of Administration (Subcutaneous, Intravenous), Application (Rheumatoid Arthritis, Psoriasis, IBD, Asthma), End-user - Global Forecast 2024 - 2032

出版日期: 2024年06月27日 | 出版商:

Global Market Insights Inc. | 英文 140 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

受生物技術進步和自體免疫疾病盛行率上升的推動，2024年至2032年全球白血球介素抑制劑市場複合年成長率將超過12%。根據全球自體免疫研究所的數據，自體免疫疾病影響工業化國家 5% 至 10% 的人口。儘管研究表明，發展中國家自體免疫疾病的盛行率較低，但正在逐漸增加，其中類風濕性關節炎和牛皮癬是最常見的。

不斷的研發努力導致了新的、更有效的白細胞介素抑制劑的推出，增強了針對健康狀況的治療選擇。此外，對自體免疫疾病的認知不斷提高和早期診斷正在推動對標靶治療的更高需求，與傳統治療相比，標靶治療更有效且副作用更少。

整個白細胞介素抑制劑市場根據類型、給藥途徑、應用、最終用戶和地區進行分類。

由於 IL-17 在治療銀屑病和僵直性脊椎炎發炎性疾病方面具有針對性功效，因此到 2032 年，IL-17 領域將錄得良好的複合年成長率。這些抑制劑透過特異性阻斷 IL-17 細胞因子而取得了顯著的臨床成功，IL-17 細胞因子在這些疾病的發病機制中發揮著至關重要的作用。與更廣泛的免疫抑制療法相比，這種有針對性的方法可以更有效地減輕症狀並最大限度地減少副作用，從而改善患者的治療效果。患者越來越偏好副作用較少的治療方法，這有利於 IL-17 抑制劑的採用。

由於治療藥物的快速有效輸送，靜脈 (IV) 領域預計到 2032 年將佔據顯著的行業佔有率。靜脈注射可確保血液中快速達到高藥物濃度，這對於控制急性發炎和最佳化治療結果至關重要。此外，靜脈注射途徑通常可以控制和精確劑量，從而提高治療效果和患者依從性。對快速有效的治療反應的需求正在增加靜脈注射的使用。

北美白細胞介素抑制劑產業在 2024 年至 2032 年間將實現顯著的複合年成長率。自體免疫疾病的盛行率不斷上升，加上尋求有效和有針對性的治療的患者人數不斷增加，刺激了需求。此外，北美領先製藥公司的存在以及新藥快速的法規核准流程進一步加速了市場擴張。

產業生態系統分析
產業影響力
- 成長動力
  - 全球自體免疫疾病盛行率不斷上升
  - 老年人口不斷增加
  - 提高消費者意識
  - 生物療法的技術進步
- 產業陷阱與挑戰
  - 治療費用高
  - 副作用和不良反應
成長潛力分析
管道分析
監管環境
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司矩陣分析
公司市佔率分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按類型，2021 - 2032

主要趨勢
IL-1抑制劑
IL-2抑制劑
IL-5抑制劑
IL-6抑制劑
IL-17抑制劑
IL-23抑制劑
其他類型

第 6 章：市場估計與預測：按管理途徑，2021 年至 2032 年

主要趨勢
皮下注射（SC）
靜脈注射 (IV)

第 7 章：市場估計與預測：按應用分類，2021 - 2032

主要趨勢
類風濕關節炎
牛皮癬
發炎性腸道疾病（IBD）
氣喘
其他應用

第 8 章：市場估計與預測：按最終用戶分類，2021 - 2032 年

主要趨勢
醫院
專科診所
研究和學術機構

第 9 章：市場估計與預測：按地區分類，2021 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

Abbvie Inc.
Biogen Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Fujifilm Kyowa Kirin Biologics Co., Ltd.
Genentech USA, Inc.
Janssen Pharmaceutical Companies (Johnson and Johnson)
Novartis AG
Regeneron Pharmaceuticals, Inc.
Samsungbioepis Co,.Ltd.
Sanofi
Sobi, Inc.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceuticals Industries Ltd.
UCB S.A

簡介目錄

Product Code: 10044

Global Interleukin Inhibitors Market will experience over 12% CAGR from 2024 to 2032, bolstered by advancements in biotechnology and the increasing prevalence of autoimmune diseases. According to the Global Autoimmune Institute, autoimmune diseases impact between 5 to 10% of the population in industrialized countries. Although research indicates that the prevalence of autoimmune diseases is lower in developing nations, it is gradually increasing, with rheumatoid arthritis and psoriasis being among the most common.

Constant R&D efforts are leading to the introduction of new and more effective interleukin inhibitors, enhancing treatment options for health conditions. Additionally, the rising awareness and early diagnosis of autoimmune disorders are contributing to higher demand for targeted therapies, which are more efficient and have fewer side effects compared to traditional treatments.

The overall interleukin inhibitors market is sorted based on type, route of administration, application, end-user, and region.

The IL-17 segment will record a decent CAGR through 2032, due to their targeted efficacy in treating inflammatory conditions such as psoriasis and ankylosing spondylitis. These inhibitors have demonstrated significant clinical success by specifically blocking the IL-17 cytokine, which plays a crucial role in the pathogenesis of these diseases. This targeted approach improves patient outcomes by reducing symptoms more effectively and minimizes side effects compared to broader immunosuppressive therapies. The growing patient preference for therapies with fewer side effects is favoring the adoption of IL-17 inhibitors.

The intravenous (IV) segment is slated to record a notable industry share by 2032, due to rapid and effective delivery of therapeutics. IV administration ensures that high drug concentrations are achieved quickly in the bloodstream, which is crucial for managing acute inflammatory conditions and optimizing therapeutic outcomes. Additionally, the IV route often allows for controlled and precise dosing, enhancing treatment efficacy and patient adherence. The need for swift and potent therapeutic responses is augmenting the uptake of IV delivery.

North America interleukin inhibitors industry will record a remarkable CAGR between 2024 and 2032. The region's advanced healthcare infrastructure and significant investment in biotechnology research facilitate the development and adoption of innovative solutions. The increasing prevalence of autoimmune diseases, coupled with a rising patient population seeking effective and targeted therapies, fuels demand. Furthermore, the presence of leading pharmaceutical companies and the rapid regulatory approval process for new drugs in North America is further accelerating the market expansion.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of autoimmune disease globally
  - 3.2.1.2 Growing elderly population
  - 3.2.1.3 Increasing consumer awareness
  - 3.2.1.4 Technological advancements in biologic therapies
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of the treatment
  - 3.2.2.2 Side effects and adverse reactions
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 IL-1 inhibitors
5.3 IL-2 inhibitors
5.4 IL-5 inhibitors
5.5 IL-6 inhibitors
5.6 IL-17 inhibitors
5.7 IL-23 inhibitors
5.8 Other types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Subcutaneous (SC)
6.3 Intravenous (IV)

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Rheumatoid arthritis
7.3 Psoriasis
7.4 Inflammatory bowel disease (IBD)
7.5 Asthma
7.6 Other applications

Chapter 8 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital
8.3 Specialty clinics
8.4 Research and academic institutes

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa